Profusa, Inc.

Profusa, Inc. is a digital health technology company based in Berkeley, California. Originally incorporated as Northview Acquisition Corp., the company completed a business combination on July 11, 2025, and subsequently changed its name to Profusa, Inc. Over the last twelve years, Profusa has invested more than $100 million from venture investors and U.S. research institutions, including approximately $30 million from the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH). This investment has been used to develop a unique biosensor platform. This platform is designed to be easily injected subcutaneously, providing real-time, individual biochemistry in a cost-effective manner, and functions for more than six times longer than existing best-in-class solutions. Profusa's Lumee™ technology is a platform, not a single product, with the potential to launch products for multiple applications. The company's strategy has involved significant investment in developing and protecting its technology as a private company, initially focusing on Europe due to traditionally lower regulatory barriers compared to the U.S. Profusa has validated its technology and obtained CE approval in the European Union (EU) for its first product, Lumee Oxygen. The company is currently working to meet new Medical Device Regulation (MDR) requirements in Europe. In 2026, Profusa plans to launch Lumee Oxygen in the U.S., pending approval by the U.S. Food and Drug Administration (FDA), for sophisticated wound care management through a distribution partner. The accessible markets for Profusa's technology extend beyond the U.S. and the EU.